RT Journal Article
SR Electronic
T1 Safety of endovascular therapy for symptomatic intracranial artery stenosis: a national prospective registry
JF Stroke and Vascular Neurology
JO Stroke Vasc Neurol
FD BMJ Publishing Group Ltd
SP 166
OP 171
DO 10.1136/svn-2021-000979
VO 7
IS 2
A1 Wang, Yabing
A1 Wang, Tao
A1 Dmytriw, Adam Andrew
A1 Yang, Kun
A1 Jiao, Liqun
A1 Shi, Huaizhang
A1 Lu, Jie
A1 Li, Tianxiao
A1 Huang, Yujie
A1 Zhao, Zhenwei
A1 Wu, Wei
A1 Wan, Jieqing
A1 Sun, Qinjian
A1 Hong, Bo
A1 Li, Yongli
A1 Zhang, Liyong
A1 Chu, Jianfeng
A1 Cheng, Qiong
A1 Cai, Yiling
A1 Wang, Pengfei
A1 Luo, Qi
A1 Yang, Hua
A1 Dong, Baijing
A1 Zhang, Yang
A1 Zhao, Jun
A1 Chen, Zuoquan
A1 Li, Wei
A1 Bai, Xiaoxin
A1 He, Weiwen
A1 Cai, Xueli
A1 Ti, Maimai
A1 Zaidat, Osama O
YR 2022
UL http://svn.bmj.com/content/7/2/166.abstract
AB Introduction The safety outcomes of endovascular therapy for intracranial artery stenosis in a real-world stetting are largely unknown. The Clinical Registration Trial of Intracranial Stenting for Patients with Symptomatic Intracranial Artery Stenosis (CRTICAS) was a prospective, multicentre, real-world registry designed to assess these outcomes and the impact of centre experience.Methods 1140 severe, symptomatic intracranial arterial stenosis (ICAS) patients treated with endovascular therapy were included from 26 centres, further divided into three groups according to the annual centre volume of intracranial angioplasty and stent placement procedures over 2 years: (1) high volume for ≥25 cases/year; (2) moderate volume for 10–25 cases/year and (3) low volume for <10 cases/year.Results The rate of 30-day stroke, transient ischaemic attack or death was 9.7% (111), with 5.4%, 21.1% and 9.7% in high-volume, moderate-volume and low-volume centres, respectively (p<0.05). Multivariable logistic regression confirmed high-volume centres had a significantly lower primary endpoint compared with moderate-volume centres (OR=0.187, 95% CI: 0.056 to 0.627; p≤0.0001), while moderate-volume and low-volume centres showed no significant difference (p=0.8456).Conclusion Compared with the preceding randomised controlled trials, this real-world, prospective, multicentre registry shows a lower complication rate of endovascular treatment for symptomatic ICAS. Non-uniform utilisation in endovascular technology, institutional experience and patient selection in different volumes of centres may have an impact on overall safety of this treatment.